{"DataElement":{"publicId":"2675153","version":"2","preferredName":"Chronic Myelogenous Leukemia Prior Transplantation Hematologic Complete Remission Phase Category","preferredDefinition":"A description of the chronic myelogenous leukemia hematologic phase prior to transplantation.","longName":"CML_HEM_CR_PRG_CLASS","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2675149","version":"1","preferredName":"Chronic Myelogenous Leukemia Prior Transplantation Hematologic Complete Remission","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic; an initial indolent chronic phase is followed by an accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001)._Earlier in time or order._The grafting of tissues from one individual to another or place to place within a single individual._Pertaining to or related to the blood and blood-forming organs._The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","longName":"CML_HEM_CR","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2500393","version":"1","preferredName":"CML","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","longName":"C3174","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1995DB3E-65B1-6546-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"ONEDATA","dateModified":"2006-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2682775","version":"1","preferredName":"Prior Transplantation Hematologic CR","preferredDefinition":"Earlier in time or order.:The grafting of tissues from one individual to another or place to place within a single individual.:Pertaining to or related to the blood and blood-forming organs.:The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","longName":"C25629:C15342:C62780:C4870","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A696D1E-1BE1-1125-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-18","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-18","modifiedBy":"ONEDATA","dateModified":"2007-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"38DD107B-4AA7-6B5C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2675138","version":"1.1","preferredName":"CML Phase Category","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic; an initial indolent chronic phase is followed by an accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001)._A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle._This term is used informally to mean a class of things.","longName":"2675138v1.1","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Chronic phase","valueDescription":"Chronic Phase Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"2675140","version":"1","preferredName":"Chronic Phase Chronic Myelogenous Leukemia","longName":"2675140","preferredDefinition":"A phase of chronic myelogenous leukemia in which the peripheral blood smear shows leukocytosis due mainly to neutrophils in different stages of maturation.  Blasts usually account for less than 2% of the white blood cells counts.  The platelet count is normal or increased.  Thrombocytopenia is very uncommon during the chronic phase.  Most patients have mild anemia.  The bone marrow biopsy is hypercellular due to increased numbers of neutrophils and their precursors.  Blasts usually account for fewer than 5% of the marrow cells, and more than 10% indicates transformation to the accelerated phase.  Megakaryocytes are smaller than normal and have hypolobated nuclei.  The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.  Most patients with chronic myelogenous leukemia are diagnosed in the chronic phase, which usually has an insidious onset and may last from several months to several years. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3175","definition":"A phase of chronic myeloid leukemia in which the peripheral blood smear shows leukocytosis due mainly to neutrophils in different stages of maturation.  Blasts usually account for less than 2% of the white blood cells counts.  The platelet count is normal or increased.  Thrombocytopenia is very uncommon during the chronic phase.  Most patients have mild anemia.  The bone marrow biopsy is hypercellular due to increased numbers of neutrophils and their precursors.  Blasts usually account for fewer than 5% of the marrow cells, and more than 10% indicates transformation to the accelerated phase.  Megakaryocytes are smaller than normal and have hypolobated nuclei.  The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.  Most patients with chronic myelogenous leukemia are diagnosed in the chronic phase, which usually has an insidious onset and may last from several months to several years. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38DBE882-E410-674F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F975C05E-663A-B624-E040-BB89AD432676","beginDate":"2007-08-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-05-15","modifiedBy":"ONEDATA","dateModified":"2014-05-15","deletedIndicator":"No"},{"value":"Blast phase","valueDescription":"Blast Phase Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"2675142","version":"1","preferredName":"Blast Phase Chronic Myelogenous Leukemia","longName":"2675142","preferredDefinition":"An advanced phase of chronic myelogenous leukemia.  It is characterized a. by the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or b. an extramedullary proliferation of blasts, and/or c. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C9110","definition":"An advanced phase of chronic myeloid leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38DBE882-E438-674F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F975C05E-6693-B624-E040-BB89AD432676","beginDate":"2007-08-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-05-15","modifiedBy":"ONEDATA","dateModified":"2014-05-15","deletedIndicator":"No"},{"value":"Hematologic complete remission","valueDescription":"Hematologic CR","ValueMeaning":{"publicId":"2675145","version":"1","preferredName":"Hematologic CR","longName":"2675145","preferredDefinition":"Pertaining to or related to the blood and blood-forming\r\norgans.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38DBE882-E488-674F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F975C05E-6658-B624-E040-BB89AD432676","beginDate":"2007-08-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-05-15","modifiedBy":"ONEDATA","dateModified":"2014-05-15","deletedIndicator":"No"},{"value":"Accelerated Phase","valueDescription":"Accelerated Phase Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"3304774","version":"1","preferredName":"Accelerated Phase Chronic Myelogenous Leukemia","longName":"3304774","preferredDefinition":"A phase of chronic myelogenous leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3173","definition":"A phase of chronic myeloid leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1E102A3-9517-BD84-E040-BB89AD432297","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F975C05E-6689-B624-E040-BB89AD432676","beginDate":"2007-08-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-05-15","modifiedBy":"ONEDATA","dateModified":"2014-05-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2677055","version":"1","preferredName":"CML Phase Category","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003:Phase; any distinct time period in a sequence of events:Category; used informally to mean a class of things.","longName":"C3174:C25257:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Phase","conceptCode":"C25257","definition":"A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3962C2E7-37D5-03A4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-05","modifiedBy":"ONEDATA","dateModified":"2007-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F975C05E-6623-B624-E040-BB89AD432676","latestVersionIndicator":"Yes","beginDate":"2014-05-15","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-05-15","modifiedBy":"NYCHM","dateModified":"2014-09-05","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedDiagnosis:diseaseStatusCode","type":"HCT_BRIDG","context":"NHLBI"},{"name":"pre_ted_cml_sts_pre_treat","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"BRIDG mapping path for CDE:2675153","type":"BRIDG Mapping Path","description":"\"PerformedDiagnosis.diseaseStatusCode [pre] WHERE PerformedDiagnosis.value [pre] = \"\"Chronic Myelogenous Leukemia(CML)\"\" AND PerformedDiagnosis [pre] > PerformedObservation.methodCode = \"\"hematologic\"\" AND PerformedDiagnosis [pre] > PerformedSubstanceAdministration > DefinedSubstranceAdministration.nameCode = \"\"Administer Hematopoietic Cell Product{ Transplantation}\"\" AND PerformedDiagnosis [pre] > Subject >  PerformedDiagnosis.diseaseStatusCode [post] = \"\"complete remission\"\" AND PerformedDiagnosis [post] > PerformedObservation.dateRange IS GREATER THAN PerformedSubstanceAdministration.dateRange\"","url":null,"context":"NHLBI"},{"name":"If the CML was in hematologic","type":"Preferred Question Text","description":"If the CML was in hematologic complete remission, what was the disease status before treatment?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CADA49F4-E010-135F-E053-4EBD850A4DDD","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-08-31","modifiedBy":"KUMMEROA","dateModified":"2021-08-31","changeDescription":". 2021-8-31 ak Versioned due to newer VD. 2021-6-3 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}